Immune checkpoint inhibitors, centered on PD-1/PD-L1 inhibitors, inhibit immune checkpoints to downregulate immune responses and enhance anti-tumor immunity by blocking the interaction between immune checkpoints and T lymphocytes (20, 21). Here, CD274 is linked to neoplasm.